Clinical Trials Browser

Phase 2 × Lasofoxifene × Clear all

NCT01042379 2026-03-13

I-SPY

Phase 2 Recruiting

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT03781063 2026-01-28

Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

Phase 2 Completed

Breast Neoplasms

NCT04432454 2025-02-13

ELAINEII

Phase 2 Completed

Breast Neoplasms